Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar ...
Novartis plans to cut as many as 680 jobs in development, Sanofi's pipeline reprioritization project will result in layoffs.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Due to slow uptake of its Humira biosimilar Cyltezo in the U.S., Boehringer Ingelheim is laying off an undisclosed number of ...
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” ...
US stocks were mostly lower on Thursday with the S&P 500 and Nasdaq falling for the fifth straight day as another rise in ...
Even with discounts that reach as high as 86%, Humira biosimilars are finding it difficult to take market share away from the ...
From one Swiss CDMO to another. That’s the course for Wolfgang Wienand, who plans to jump from his role as Siegfried’s CEO ...
In this article, we will take a detailed look at Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024. For a quick ...
Wall Street stocks were in the green early on Monday as retail sales boosted sentiment and market participants prepared for ...